Annals of Nuclear Medicine最新文献

{"title":"Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022","authors":"Atsutaka Okizaki, Yoshihiro Nishiyama, Yoshitaka Inui, Hideki Otsuka, Kentaro Takanami, Masatoyo Nakajo, Koya Nakatani, Munenobu Nogami, Kenji Hirata, Yukito Maeda, Mana Yoshimura, Hiroshi Wakabayashi","doi":"10.1007/s12149-024-01905-9","DOIUrl":"10.1007/s12149-024-01905-9","url":null,"abstract":"<div><p>Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data. A total of 1095 institutes responded to the survey, including 364 positron emission tomography (PET) centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1299 in total, with 2.5% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 83.8% and 35.5%, respectively. The number of single-photon tracer studies in 2022 was 1.11 million which means increase in 2.7% in 5 years. Bone scintigraphy was a leading examination (31.0%), followed by myocardial scintigraphy (27.1%) and cerebral perfusion study (23.8%) in order. The percentage of SPECT studies showed an increase from 63.5% in previous survey to 66.8% in this survey. PET centers have also increased from 389 to 412, as compared with the previous one. One hundred and twenty-two PET centers have installed one or two in-house cyclotrons. Increasing trends of the PET studies were observed from 1992 to 2017, the trend changed and PET studies showed 1.5% decrease in 5 years. <sup>18</sup>F-FDG accounted for 98.6% (610,497 examinations). PET examinations using <sup>11</sup>C-methionine, <sup>13</sup>N-NH<sub>3</sub> and <sup>11</sup>C-PIB have decreased, with 1624, 2146 and 525 examinations, respectively in 2022. The total number of nuclear medicine examination was eventually increased by 1.0%. Therapies for pheochromocytoma or paraganglioma (PPGL) with <sup>131</sup>I-MIBG and for neuroendocrine tumor with <sup>177</sup>Lu-DOTA-TATE were newly started, however, a total number of targeted radionuclide therapy was decreased by 17.7% because <sup>131</sup>I-radioiodine and <sup>223</sup>Ra targeted therapies were decreased and supply of some radioisotopes was discontinued. <sup>131</sup>I-radioiodine targeted therapy showed a decrease in 5 years (− 15.9%), including 4099 patients for thyroid cancer. The number of out-patient thyroid bed ablation therapy with 1110 MBq of <sup>131</sup>I was also decreased to 1015 per year. The number of admission rooms specialized for radionuclide targeted therapy increased from 157 to 160. The number of <sup>223</sup>Ra targeted therapies for castration-resistant metastatic prostate cancer (mCRPC) was 1041 patients. This survey was performed during COVID-19 pandemic, however, total number of nuclear medicine examinations was almost same as previous survey (+ 1.0%). Radionuclide therapies with <sup>131</sup>I-MIBG and <sup>177</sup>Lu-DOTA-TATE were newly started, and new radionuclide therapy ","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 4","pages":"315 - 327"},"PeriodicalIF":2.5,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Properties of [18F]FAPI monitoring of acute radiation pneumonia versus [18F]FDG in mouse models","authors":"Mingyu Liu,&nbsp;An Yao,&nbsp;Zili Li,&nbsp;Jianping Zhang,&nbsp;Caiyue Ren,&nbsp;Yuyun Sun,&nbsp;Guang Ma,&nbsp;Yun Sun,&nbsp;Jingyi Cheng","doi":"10.1007/s12149-024-01903-x","DOIUrl":"10.1007/s12149-024-01903-x","url":null,"abstract":"<div><h3>Objective</h3><p>In this study, the uptake characteristics of [¹⁸F]fibroblast activation protein inhibitor (FAPI) molecular imaging probe were investigated in acute radiation pneumonia and lung cancer xenografted mice before and after radiation to assess the future applicability of [¹⁸F]FAPI positron emission tomography/computed tomography (PET/CT) imaging in early radiotherapy response.</p><h3>Methods</h3><p>Initially, the biodistribution of [¹⁸F]FAPI tracer in vivo were studied in healthy mice at each time-point. A comparison of [¹⁸F]FAPI and [¹⁸F]fluorodeoxyglucose (FDG) PET/CT imaging efficacy in normal ICR, LLC tumor-bearing mice was evaluated. A radiation pneumonia model was then investigated using a gamma counter, small animal PET/CT, and autoradiography. The uptake properties of [¹⁸F]FAPI in lung cancer and acute radiation pneumonia were investigated using autoradiography and PET/CT imaging in mice.</p><h3>Results</h3><p>The tumor area was visible in [¹⁸F]FAPI imaging and the tracer was swiftly eliminated from normal tissues and organs. There was a significant increase of [¹⁸F]FDG absorption in lung tissue after radiotherapy compared to before radiotherapy, but no significant difference of [¹⁸F]FAPI uptake under the same condition. Furthermore, both the LLC tumor volume and the expression of FAP-ɑ decreased after thorax irradiation. Correspondingly, there was no notable [¹⁸F]FAPI uptake after irradiation, but there was an increase of [¹⁸F]FDG uptake in malignancies and lungs.</p><h3>Conclusions</h3><p>The background uptake of [¹⁸F]FAPI is negligible. Moreover, the uptake of [¹⁸F]FAPI may not be affected by acute radiation pneumonitis compared to [¹⁸F]FDG, which may be used to more accurately evaluate early radiotherapy response of lung cancer with acute radiation pneumonia.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 5","pages":"360 - 368"},"PeriodicalIF":2.5,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139970783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor 11C-methionine PET/CT imaging","authors":"Koichiro Kaneko,&nbsp;Michinobu Nagao,&nbsp;Kaori Ueda,&nbsp;Atsushi Yamamoto,&nbsp;Shuji Sakai","doi":"10.1007/s12149-024-01908-6","DOIUrl":"10.1007/s12149-024-01908-6","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the potential of whole-body digital ¹¹C-methionine (MET) PET/CT imaging for simultaneous evaluation of thoracic cancer patients suspected of local recurrence (LR) after stereotactic radiosurgery (SRS) for brain metastasis.</p><h3>Methods</h3><p>A total of 45 lung or breast cancer patients suspected of LR after SRS were investigated using brain and whole-body MET-PET/CT scans. We compared the tumor-to-normal ratio (TNR) and maximum standardized uptake values (SUVmax) between patients with LR and radiation necrosis (RN) and performed receiver operating characteristic (ROC) analyses. We also investigated associations among extracranial recurrence, intracranial recurrence, primary site, and initial treatment type.</p><h3>Results</h3><p>A total of 44 LR and 14 RN lesions were analyzed. In the ROC analyses for differentiating LR from RN, TNR showed higher area under the curve (AUC) (0.82) than SUVmax (0.79), and the cutoff TNR value (2.12) was higher than current cutoff values of conventional PET systems. The whole-body scans detected extracranial recurrences in 31.1% of the patients. Recurrence rates were not significantly correlated with existence of intracranial recurrence or primary site, but patients who underwent non-surgical treatment (consisting of stage III/ IV patients according to the Union for International Cancer Control TNM classification or small-cell lung cancer patients) showed significantly higher recurrence than the surgically treated patients (68.8% vs. 10.3%, <i>p</i> = 0.0001).</p><h3>Conclusion</h3><p>In digital MET-PET/CT imaging, TNR was a more useful parameter to differentiate LR from RN than SUVmax, and the cutoff value was higher than those with conventional PET systems. Additional whole-body scans could detect extracranial recurrence and would be especially useful for advanced thoracic cancer patients who underwent non-surgical treatment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 4","pages":"278 - 287"},"PeriodicalIF":2.5,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139929694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A fully automatic deep learning-based method for segmenting regions of interest and predicting renal function in pediatric dynamic renal scintigraphy","authors":"Xueli Ji,&nbsp;Guohui Zhu,&nbsp;Jinyu Gou,&nbsp;Suyun Chen,&nbsp;Wenyu Zhao,&nbsp;Zhanquan Sun,&nbsp;Hongliang Fu,&nbsp;Hui Wang","doi":"10.1007/s12149-024-01907-7","DOIUrl":"10.1007/s12149-024-01907-7","url":null,"abstract":"<div><h3>Objective</h3><p>Accurate delineation of renal regions of interest (ROIs) is critical for the assessment of renal function in pediatric dynamic renal scintigraphy (DRS). The purpose of this study was to develop and evaluate a deep learning (DL) model that can fully automatically delineate renal ROIs and calculate renal function in pediatric ^99mTechnetium-ethylenedicysteine (^99mTc-EC) DRS.</p><h3>Methods</h3><p>This study retrospectively analyzed 1,283 pediatric DRS data at a single center from January to December 2018. These patients were divided into training set (<i>n</i> = 1027), validation set (<i>n</i> = 128), and testing set (<i>n</i> = 128). A fully automatic segmentation of ROIs (FASR) model was developed and evaluated. The pixel values of the automatically segmented ROIs were calculated to predict renal blood perfusion rate (BPR) and differential renal function (DRF). Precision, recall rate, intersection over union (IOU), and Dice similarity coefficient (DSC) were used to evaluate the performance of FASR model. Intraclass correlation (ICC) and Pearson correlation analysis were used to compare the consistency of automatic and manual method in assessing the renal function parameters in the testing set.</p><h3>Results</h3><p>The FASR model achieved a precision of 0.88, recall rate of 0.94, IOU of 0.83, and DSC of 0.91. In the testing set, the r values of BPR and DRF calculated by the two methods were 0.94 (<i>P</i> &lt; 0.01) and 0.97 (<i>P</i> &lt; 0.01), and the ICCs (95% confidence interval CI) were 0.94 (0.90—0.96) and 0.94 (0.91—0.96).</p><h3>Conclusion</h3><p>We propose a reliable and stable DL model that can fully automatically segment ROIs and accurately predict renal function in pediatric ^99mTc-EC DRS.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 5","pages":"382 - 390"},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139904769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Cyclosporin H on ischemic injury and neutrophil infiltration in cerebral infarct model of rats via PET imaging","authors":"Zhihui Hong,&nbsp;Hong Xu,&nbsp;Kairu Ni,&nbsp;Yi Yang,&nbsp;Shengming Deng","doi":"10.1007/s12149-024-01900-0","DOIUrl":"10.1007/s12149-024-01900-0","url":null,"abstract":"<div><h3>Background</h3><p>Brain ischemia–reperfusion injury is a complex process, and neuroinflammation is an important secondary contributing pathological event. Neutrophils play major roles in ischemic neuroinflammation. Once activated, neutrophils express formyl peptide receptors (FPRs), which are special receptors of a class of chemoattractants and may be potential targets to regulate the activity of neutrophils and control cerebral ischemic injury. This study was aimed to explore the ameliorating effect of Cyclosporin H (CsH), a potent FPR antagonist, on brain ischemic injury by inhibiting the activation and migration of neutrophils, and improving cerebral blood flow.</p><h3>Methods</h3><p>We employed a middle cerebral artery occlusion (MCAO) Model on rats and performed behavioral, morphological, and microPET imaging assays to investigate the potential restoring efficacy of CsH on cerebral ischemic damages. Peptide N-cinnamoyl-F-(D)L-F-(D)L-F (cFLFLF), an antagonist to the neutrophil FPR with a high binding affinity, was used for imaging neutrophil distribution.</p><h3>Results</h3><p>We found that CsH had similar effect with edaravone on improving the neurobehavioral deficient symptoms after cerebral ischemia–reperfusion, and treatment with CsH also alleviated ischemic cerebral infarction. Compared with the MCAO Model group, [¹⁸F]FDG uptake ratios of the CsH and edaravone treatment groups were significantly higher. The CsH-treated groups also showed significant increases in [¹⁸F]FDG uptake at 144 h when compared with that of 24 h. This result indicates that like edaravone, treatment with both doses of CsH promoted the recovery of blood supply after cerebral ischemic event. Moreover, MCAO-induced cerebral ischemia significantly increased the radiouptake of [⁶⁸Ga]Ga-cFLFLF at 72 h after ischemia–reperfusion operation. Compared with MCAO Model group, radiouptake values of [⁶⁸Ga]-cFLFLF in both doses of CsH and edaravone groups were all decreased significantly. These results showed that both doses of CsH resulted in a similar therapeutic effect with edaravone on inhibiting neutrophil infiltration in cerebral infarction.</p><h3>Conclusion</h3><p>Potent FPR antagonist CsH is promisingly beneficial in attenuating neuroinflammation and improving neurobehavioral function against cerebral infarction. Therefore, FPR may become a novel target for regulating neuroinflammation and improving prognosis for ischemic cerebrovascular disorders.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 5","pages":"337 - 349"},"PeriodicalIF":2.5,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methyl-11C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma","authors":"Hikaru Niitsu,&nbsp;Nobuyoshi Fukumitsu,&nbsp;Keiichi Tanaka,&nbsp;Masashi Mizumoto,&nbsp;Kei Nakai,&nbsp;Masahide Matsuda,&nbsp;Eiichi Ishikawa,&nbsp;Kentaro Hatano,&nbsp;Tsuyoshi Hashimoto,&nbsp;Satoshi Kamizawa,&nbsp;Hideyuki Sakurai","doi":"10.1007/s12149-024-01901-z","DOIUrl":"10.1007/s12149-024-01901-z","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate differences in uptake regions between methyl-¹¹C-L-methionine positron emission tomography (¹¹C-MET PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI), and their impact on dose distribution, including changing of the threshold for tumor boundaries.</p><h3>Methods</h3><p>Twenty consecutive patients with grade 3 or 4 glioma who had recurrence after postoperative radiotherapy (RT) between April 2016 and October 2017 were examined. The study was performed using simulation with the assumption that all patients received RT. The clinical target volume (CTV) was contoured using the Gd-enhanced region (CTV(Gd)), the tumor/normal tissue (T/N) ratios of ¹¹C-MET PET of 1.3 and 2.0 (CTV (T/N 1.3), CTV (T/N 2.0)), and the PET-edge method (CTV(P-E)) for stereotactic RT planning. Differences among CTVs were evaluated. The brain dose at each CTV and the dose at each CTV defined by ¹¹C-MET PET using MRI as the reference were evaluated.</p><h3>Results</h3><p>The Jaccard index (JI) for concordance of CTV (Gd) with CTVs using ¹¹C-MET PET was highest for CTV (T/N 2.0), with a value of 0.7. In a comparison of pixel values of MRI and PET, the correlation coefficient for cases with higher JI was significantly greater than that for lower JI cases (0.37 vs. 0.20, <i>P</i> = 0.007). D50% of the brain in RT planning using each CTV differed significantly (<i>P</i> = 0.03) and that using CTV (T/N 1.3) were higher than with use of CTV (Gd). V90% and V95% for each CTV differed in a simulation study for actual treatment using CTV (Gd) (<i>P</i> = 1.0 × 10^–7 and 3.0 × 10^–9, respectively) and those using CTV (T/N 1.3) and CTV (P-E) were lower than with CTV (Gd).</p><h3>Conclusions</h3><p>The region of ¹¹C-MET accumulation is not necessarily consistent with and larger than the Gd-enhanced region. A change of the tumor boundary using ¹¹C-MET PET can cause significant changes in doses to the brain and the CTV.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 4","pages":"305 - 314"},"PeriodicalIF":2.5,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabeled florescent-magnetic graphene oxide nanosheets: probing the biodistribution of a potential PET-MRI hybrid imaging agent for detection of fibrosarcoma tumor","authors":"Ahad Amiri,&nbsp;Yousef Fazaeli,&nbsp;Hakimeh Zare,&nbsp;Mohammad Eslami-Kalantari,&nbsp;Shahzad Feizi,&nbsp;Zahra Shahedi,&nbsp;Mohammadreza Afrasyabi","doi":"10.1007/s12149-024-01902-y","DOIUrl":"10.1007/s12149-024-01902-y","url":null,"abstract":"<div><h3>Purpose</h3><p>Radiolabeled graphene oxide (GO) nanosheets has been one of the most extensively studied nanoplatform for in vivo radioisotope delivery. Herein, we describe the functionalization of the surface of GO nanosheets with Fe₃O₄ magnetic nanoparticles, cysteine amino acid as an interface ligand, and cadmium telluride quantum dots.</p><h3>Materials and Methods</h3><p>To enable In vivo PET imaging, the GO@Fe₃O₄-cys-CdTe QDs were labeled with ⁶⁸Ga to yield [⁶⁸Ga] Ga-Go@ Fe₃O₄-Cys-CdTe QDs. Furthermore, serum stability tests were performed and the biological behavior of the nanocomposite was evaluated in rats bearing fibrosarcoma tumor.</p><h3>Results</h3><p>Liver, blood and tumor were the most accumulated sites at 1 h after the injection, and the radiolabeled nanocomposite as a PET/MRI imaging agent showed fast depletion from body and acceptable tumor uptake.</p><h3>Conclusion</h3><p>Magnetic (Fe₃O₄) and fluorescent components (CdTe QDs) along with a positron-emitting radionuclide will help to design a multimodal imaging system (PET/MRI/OI) which will offer the advantages of combined imaging techniques and further possible used in localized radionuclide therapy. Overall, [⁶⁸Ga] Ga-GO@Fe₃O₄-cys-CdTe QDs nanocomposite shows great promise as a radiolabeled imaging agent owing to high accumulation in tumor region.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 5","pages":"350 - 359"},"PeriodicalIF":2.5,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis","authors":"Tejasvini Singhal,&nbsp;Parneet Singh,&nbsp;Girish Kumar Parida,&nbsp;Kanhaiyalal Agrawal","doi":"10.1007/s12149-024-01904-w","DOIUrl":"10.1007/s12149-024-01904-w","url":null,"abstract":"<div><p>Fluoro-deoxy glucose positron emission tomography/computed tomography (PET/CT), the workhorse of nuclear medicine, has limited utility for renal cell carcinoma (RCC), particularly clear cell variant. Thus, various other tracers have been tried for evaluation of RCC. One of the most promising targets for radiotracers is prostate-specific membrane antigen (PSMA) expressed in abundance in carcinoma-associated neo-vasculature. Thus, we tried to review and analyse the role of PSMA-targeted PET/CT in evaluation of RCC. Databases like PubMed, EMBASE and SCOPUS were searched for original studies published on PSMA-targeted PET/CT in RCC till 30 September 2023. Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) checklist was used to assess the included studies. Pooled sensitivity and specificity were calculated and represented with 95% confidence intervals (95%CI). Heterogeneity in the studies was assessed by <i>I</i>-square index. Pooled sensitivity and specificity of PSMA-targeted PET/CT for detection of local disease estimates were 87.2% (95%CI: 77–94%) and 100% (95%CI: 92.9–100%), respectively. Pooled sensitivity and specificity for detection of local recurrent disease are 100% (95%CI: 71.5–100%) and 100% (95%CI: 89.4–100%), respectively. Pooled sensitivity and specificity for detection of metastatic disease are 92% (95%CI: 86.2–96%) and 96.9% (95%CI: 83.8–99.9%), respectively. Pooled sensitivity of PSMA-targeted PET/CT for detection of clear cell renal cell carcinoma (ccRCC) and non-ccRCC are 94.7% (95%CI: 88–98.3%) and 75% (95%CI: 35–96.8%), respectively. PSMA-targeted PET-CT demonstrated better diagnostic efficacy for the detection of recurrent RCC. Whilst for staging RCC, it had higher specificity but lower sensitivity. Thus, it can serve as a non-invasive adjuvant tool to conventional imaging in the evaluation of staging of RCC, particularly clear cell variant.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 3","pages":"176 - 187"},"PeriodicalIF":2.5,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139715748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A first-in-man study of [18F] FEDAC: a novel PET tracer for the 18-kDa translocator protein","authors":"Kentaro Tamura,&nbsp;Ryuichi Nishii,&nbsp;Kotaro Tani,&nbsp;Hiroki Hashimoto,&nbsp;Kazunori Kawamura,&nbsp;Ming-Rong Zhang,&nbsp;Takamasa Maeda,&nbsp;Kana Yamazaki,&nbsp;Tatsuya Higashi,&nbsp;Masahiro Jinzaki","doi":"10.1007/s12149-023-01895-0","DOIUrl":"10.1007/s12149-023-01895-0","url":null,"abstract":"<div><h3>Purpose</h3><p>N-benzyl-N-methyl-2-[7, 8-dihydro-7-(2-[¹⁸F] fluoroethyl) -8-oxo-2-phenyl-9H-purin-9-yl] acetamide ([¹⁸F] FEDAC) is a novel positron emission tomography (PET) tracer that targets the translocator protein (TSPO; 18 kDa) in the mitochondrial outer membrane, which is known to be upregulated in various diseases such as malignant tumors, neurodegenerative diseases, and neuroinflammation. This study presents the first attempt to use [¹⁸F]FEDAC PET/CT and evaluate its biodistribution as well as the systemic radiation exposure to the radiotracer in humans.</p><h3>Materials and Methods</h3><p>Seventeen whole-body [¹⁸F]FEDAC PET/CT (injected dose, 209.1 ± 6.2 MBq) scans with a dynamic scan of the upper abdomen were performed in seven participants. Volumes of interest were assigned to each organ, and a time–activity curve was created to evaluate the biodistribution of the radiotracer. The effective dose was calculated using IDAC-Dose 2.1.</p><h3>Results</h3><p>Immediately after the intravenous injection, the radiotracer accumulated significantly in the liver and was subsequently excreted into the gastrointestinal tract through the biliary tract. It also showed high levels of accumulation in the kidneys, but showed minimal migration to the urinary bladder. Thus, the liver was the principal organ that eliminated [¹⁸F] FEDAC. Accumulation in the normal brain tissue was minimal. The effective dose estimated from biodistribution in humans was 19.47 ± 1.08 µSv/MBq, and was 3.60 mSV for 185 MBq dose.</p><h3>Conclusion</h3><p>[¹⁸F]FEDAC PET/CT provided adequate image quality at an acceptable effective dose with no adverse effects. Therefore, [¹⁸F]FEDAC may be useful in human TSPO-PET imaging.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 4","pages":"264 - 271"},"PeriodicalIF":2.5,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of PET/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review","authors":"Shashi B. Singh,&nbsp;Sambhawana Bhandari,&nbsp;Sadikshya Bhandari,&nbsp;Samikshya Bhandari,&nbsp;Rajshree Singh,&nbsp;William Y. Raynor,&nbsp;Soren Hess,&nbsp;Thomas J. Werner,&nbsp;Abass Alavi,&nbsp;Mona-Elisabeth Revheim","doi":"10.1007/s12149-023-01896-z","DOIUrl":"10.1007/s12149-023-01896-z","url":null,"abstract":"<div><p>Rheumatoid Arthritis (RA) is a systemic inflammatory disorder that commonly presents with polyarthritis but can have multisystemic involvement and complications, leading to increased morbidity and mortality. The diagnosis of RA continues to be challenging due to its varied clinical presentations. In this review article, we aim to determine the potential of PET/CT to assist in the diagnosis of RA and its complications, evaluate the therapeutic response to treatment, and predict RA remission. PET/CT has increasingly been used in the last decade to diagnose, monitor treatment response, predict remissions, and diagnose subclinical complications in RA. PET imaging with [¹⁸F]-fluorodeoxyglucose ([¹⁸F]-FDG) is the most commonly applied radiotracer in RA, but other tracers are also being studied. PET/CT with [¹⁸F]-FDG, [¹⁸F]-NaF, and other tracers might lead to early identification of RA and timely evidence-based clinical management, decreasing morbidity and mortality. Although PET/CT has been evolving as a promising tool for evaluating and managing RA, more evidence is required before incorporating PET/CT in the standard clinical management of RA.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 3","pages":"165 - 175"},"PeriodicalIF":2.5,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}